netherlands

 

 

COST Action Members from the Netherlands

 

Annemieke

Prof. Annemieke Aartsma-Rus

RESEARCH TOPIC

I am a pioneer of exon skipping for Duchenne muscular dystrophy (DMD). In the past 5 years my research has focused on generating the optimal tools and research environment for developing therapies. We have established that very low levels of dystrophin have therapeutic effects and generated a humanized mouse model allowing for the first time testing of human exon skipping compounds in preclinical studies. My group has provided detailed natural history data for regularly used muscular dystrophy models. We have established a pre-clinical "validation lab", allowing companies and patient organizations to run confirmatory studies in a standardized manner. Furthermore, my group is exploring therapies to improve muscle quality in DMD/muscular dystrophy animal models. To improve exon skipping my group has done pre-clinical studies with different chemistries and for the first time showed increased exon skipping for 2-O-methyl-phosphorothioate compounds due to muscle- and heart-homing peptide conjugates. I am collaborating to develop exon skipping for other diseases, e.g. Huntington, CADASIL. To facilitate clinical development of exon skipping technology, I am involved in multistakeholder networking and education for patients, academics and regulators.

Affiliation

Human Genetics,
Aartsma-Rus Lab
Leiden University Medical Center

Albinusdreef 2, 2333 ZA
Leiden, Netherlands

ORCID: 0000-0003-1565-654

WWW: 

 

ACTION VICE-CHAIR, MC MEMBER

MEMBER OF WG2 & WG4

KEYWORDS: exon skipping, splicing, antisense oligonucleotides, stakeholder communication

MODEL: cell culture, mice

TISSUE: brain, heart, muscle

DISORDERS: Duchene Muscular Dystrophy

Alex Garanto

Dr Alex Garanto

RESEARCH TOPIC

I started my PhD project in the field of Genetics after finishing my studies in Biology at the University of Barcelona. During my PhD, I studied the function of a frequently mutated gene in the Spanish population and I was fascinated by the eye. Since then, I have been focusing my career towards the understanding of the molecular mechanisms underlying inherited retinal diseases and search for therapeutic approaches in order to halt or delay the progression of the disease. As a postdoc, I worked on the development of antisense oligonucleotides to target one of the most recurrent mutations in inherited retinal diseases, a deep-intronic variant in the CEP290 gene. This variant leads to a pseudoexon insertion in the final transcript. Using antisense oligonucleotides this pseudoexon could be removed and the correct transcript restored. Following a similar approach, I have also been involved in the design and testing of antisense technology for different retinal genes such as ABCA4, CHM or USH2A. Currently, I am starting my own group on therapeutic DNA and RNA editing at the Department of Human Genetics of the Radboudumc. My research focuses on the development of novel strategies to correct the effect of mutations underlying inherited retinal diseases either at DNA or RNA level, as well as the development of reliable cellular (retinal) models to assess those therapeutic approaches.

Affiliation

Human Genetics,
Alex Garanto Lab
Radboudumc

Nijmegen, Netherlands

ORCID: 0000-0001-5721-1560

WWW: alex-garanto_page

 

WG2 LEADER, MC MEMBER

MEMBER OF WG2, INTERESTED IN WG3 TASKS

KEYWORDS: retinal dystrophies, splicing modulation, antisense oligonucleotides, retina, RNA therapies, mouse models, cellular models, iPSCs, eyeexon skipping, splicing, antisense oligonucleotides, stakeholder communication

MODEL: cell culture, humans, mice, zebrafish

TISSUE: eye

DISORDERS: Inherited retinal disease

 Page top

 

man

Dr Ronald Buijsen

RESEARCH TOPIC

Descriprtion

Affiliation

Human Genetics,
Willeke van Roon-Mom Lab
Leiden University Medical Center

Albinusdreef 2, 2333 ZA
Leiden, Netherlands

ORCID: 0000-0002-9722-8110

WWW: 

 

ACTION MEMBER

MEMBER OF WG2, INTERESTED IN WG1 TASKS

KEYWORDS: ataxia, repeat expansion disorders, polyglutamine diseases, SCA1, spinocerebellar ataxia type1, hiPSC, antisense oligonucleotides, neuroscience, Fragile-X associated tremor/ataxia syndrome

MODEL: cell culture, humans, mice, organoids

TISSUE: brain

DISORDERS: Neurological and neurodegenerative diseases, Neuromuscular disorders

Page top

 

woman

Dr Ingrid Verhaart

RESEARCH TOPIC

I am working on Duchenne muscular dystrophy. Currently I am working on pre-clinical research into potential therapies for DMD. This focuses both on primary and secondary therapies. We are working on the exon skipping therapy, testing potential improved version of AONs in cell and mouse models. Furthermore we are testing potential compounds that could enhance muscle quality, thereby retaining muscle tissue and function. These can be compounds for which another lab has shown positive results for DMD. Independent validation is very important to ensure the compound is indeed improving DMD pathology. It can also be interesting compounds used in other disease areas and that could be repurposed for DMD.

Affiliation

Human Genetics,
Leiden University Medical Center

Albinusdreef 2, 2333 ZA
Leiden, Netherlands

ORCID: 0000-0001-7348-7989

WWW: 

 

ACTION MEMBER

MEMBER OF WG1, INTERESTED IN WG2 & WG3 TASKS

KEYWORDS: Duchenne muscular dystrophy, muscle quality, antisense oligonucleotides, exon skipping

MODEL: cell culture, mice

TISSUE: Heart, Muscle

DISORDERS: Muscular dystrophies/atrophies, Duchene Muscular Dystrophy, Neuromuscular disorders

Page top

 

   

woman ikoneDr Willeke van ROON-MOM
Affiliation: Leiden University Medical Center, the Netherlands
ORCID: 0000-0002-3035-0533
Webpage: https://www.lumc.nl/org/humane-genetica/research/research-line-1/Polyglutaminedisorders/

COST function: Substitute MC Member
COST Working Groups: WG 1 - Delivery Strategies, WG 2 - Model systems, WG 4 - Stakeholder communication and dissemination

Research interests:
keywords: neuroscience, polyglutamine disorders, antisense oligonucleotides, iPS cells, animal models, hereditary cerebral amyloid angiopathy
disorders: Neurodegenerative disorders
tissue/organ of interest: Brain
model system(s): Cell culture, Mouse, Human

man ikoneDr Jeroen BREMER
Affiliation: University Medical Center Groningen, Groningen, Netherlands
Research Group: Peter van den Akker Group

ORCID: 0000-0002-7550-6386
Webpage:

COST function: Member
COST Working Groups: WG 1 - Delivery Strategies, WG 2 - Model systems

Research interests:
keywords: skin, Epidermolysis Bullosa, Genodermatoses, exon skipping
disorders: Dystrophic Epidermolysis Bullosa
tissue/organ of interest: Skin
model system(s): Cell culture, Mouse

man ikoneDr Rob Collin
Affiliation: Radboud UMC, Nijmegen, Netherlands
ORCID: 0000-0000-3575-2014
Webpage: https://www.radboudumc.nl/en/people/rob-collin

COST function: Member
COST Working Groups: WG 1 - Delivery Strategies, WG 2 - Model systems, WG 3 - Safety and toxicology

 

Research interests:
keywords: antisense oligonucleotides, splicing, retina, eye, organoids
disorders: Inherited retinal disease
tissue/organ of interest: Eye
model system(s): Cell culture, Mouse

 

Learn more about Researchers from DARTER's Member Countries

Belgium Bosnia and Herzegovina Croatia Cyprus Czech Republic Denmark Estonia France Germany greece Hungary Ireland Israel Italy
Latvia Malta Netherlands Norway Poland Portugal Romania Serbia Slovenia Spain Sweden Turkey United kingdom  

 

Page top

 

0
0
0
s2smodern